Overview

Avoiding Risks of Thrombosis and Bleeding in Surgery (ARTS) Trial

Status:
RECRUITING
Trial end date:
2028-12-31
Target enrollment:
Participant gender:
Summary
Avoiding Risks of Thrombosis and bleeding in Surgery (ARTS) trial is a pragmatic, international, multicenter, randomized controlled open label trial comparing a direct oral anticoagulant (DOAC) - oral factor Xa inhibitor apixaban - to no anticoagulant among 5,436 patients undergoing abdominal or pelvic surgery at sufficiently similar (and not high) risk of venous thromboembolism (VTE) and bleeding that the net impact - benefit or harm - of thromboprophylaxis remains in doubt.
Phase:
PHASE4
Details
Lead Sponsor:
Clinical Urology and Epidemiology Working Group
Collaborators:
Albany Medical College
Helsinki University Central Hospital
North Karelia Central Hospital
Oulu University Hospital
PaijatHame Central Hospital
Population Health Research Institute
Tabriz University of Medical Sciences
Tampere University Hospital
Turku University Hospital
University College, London
University of Helsinki
Treatments:
apixaban